These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
490 related articles for article (PubMed ID: 26045121)
1. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study. Kucharz J; Dumnicka P; Kuzniewski M; Kusnierz-Cabala B; Herman RM; Krzemieniecki K Tumori; 2015; 101(5):555-9. PubMed ID: 26045121 [TBL] [Abstract][Full Text] [Related]
2. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. Rini BI; Cohen DP; Lu DR; Chen I; Hariharan S; Gore ME; Figlin RA; Baum MS; Motzer RJ J Natl Cancer Inst; 2011 May; 103(9):763-73. PubMed ID: 21527770 [TBL] [Abstract][Full Text] [Related]
3. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival]. Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767 [No Abstract] [Full Text] [Related]
4. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180 [TBL] [Abstract][Full Text] [Related]
6. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860 [TBL] [Abstract][Full Text] [Related]
7. Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma. Nagyiványi K; Budai B; Bíró K; Gyergyay F; Noszek L; Küronya Z; Németh H; Nagy P; Géczi L Clin Genitourin Cancer; 2016 Aug; 14(4):314-22. PubMed ID: 26774206 [TBL] [Abstract][Full Text] [Related]
8. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off. Kondo T; Takagi T; Kobayashi H; Iizuka J; Nozaki T; Hashimoto Y; Ikezawa E; Yoshida K; Omae K; Tanabe K Jpn J Clin Oncol; 2014 Mar; 44(3):270-7. PubMed ID: 24474815 [TBL] [Abstract][Full Text] [Related]
9. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. Donskov F; Michaelson MD; Puzanov I; Davis MP; Bjarnason GA; Motzer RJ; Goldstein D; Lin X; Cohen DP; Wiltshire R; Rini BI Br J Cancer; 2015 Dec; 113(11):1571-80. PubMed ID: 26492223 [TBL] [Abstract][Full Text] [Related]
10. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Oudard S; Negrier S; Szczylik C; Pili R; Bjarnason GA; Garcia-del-Muro X; Sosman JA; Solska E; Wilding G; Thompson JA; Kim ST; Chen I; Huang X; Figlin RA J Clin Oncol; 2009 Aug; 27(22):3584-90. PubMed ID: 19487381 [TBL] [Abstract][Full Text] [Related]
11. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study. Noize P; Grelaud A; Bay JO; Chevreau C; Gross-Goupil M; Culine S; Ferrière JM; Moulin F; Robinson P; Balestra A; Lamarque S; Bernard MA; Lassalle R; Rouyer M; Droz-Perroteau C; Moore N; Fourrier-Réglat A; Ravaud A Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1561-1569. PubMed ID: 28573786 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma. Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial. Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C Oncology; 2015; 88(5):273-80. PubMed ID: 25592399 [TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. Atkinson BJ; Kalra S; Wang X; Bathala T; Corn P; Tannir NM; Jonasch E J Urol; 2014 Mar; 191(3):611-8. PubMed ID: 24018239 [TBL] [Abstract][Full Text] [Related]
15. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173 [TBL] [Abstract][Full Text] [Related]
16. Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients. Buda-Nowak A; Kucharz J; Dumnicka P; Kuzniewski M; Herman RM; Zygulska AL; Kusnierz-Cabala B Med Oncol; 2017 Apr; 34(4):68. PubMed ID: 28343336 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072 [TBL] [Abstract][Full Text] [Related]
18. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Armstrong AJ; Halabi S; Eisen T; Broderick S; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; Lusk CM; Oberg S; George DJ Lancet Oncol; 2016 Mar; 17(3):378-388. PubMed ID: 26794930 [TBL] [Abstract][Full Text] [Related]
19. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma. Shi HZ; Tian J; Chen X; Wang D; Li CL Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518 [TBL] [Abstract][Full Text] [Related]
20. Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients. Akaza H; Naito S; Ueno N; Aoki K; Houzawa H; Pitman Lowenthal S; Lee SY Jpn J Clin Oncol; 2015 Jun; 45(6):576-83. PubMed ID: 25917359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]